STOCK TITAN

Cullinan Oncology, Inc. - $CGEM STOCK NEWS

Welcome to our dedicated page for Cullinan Oncology news (Ticker: $CGEM), a resource for investors and traders seeking the latest updates and insights on Cullinan Oncology stock.

Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a forward-thinking biopharmaceutical company dedicated to establishing new standards of care for patients through innovative cancer and autoimmune therapies. The company specializes in a modality-agnostic approach, targeting key drivers of disease and harnessing the immune system to eradicate diseased cells.

With a highly experienced team of oncology professionals and drug developers, Cullinan boasts a diversified portfolio of clinical-stage assets sourced from both internal and external collaborations. This includes therapies aimed at inhibiting disease drivers or activating the immune system to address various oncology and autoimmune indications.

Recent Achievements:

  • CLN-617: A first-in-class cytokine therapy combining IL-2 and IL-12 for intratumoral injection, shown to activate a broad immune response.
  • CLN-619: A first-in-class monoclonal antibody for relapsed/refractory multiple myeloma, aimed at restoring immune recognition of tumor cells.
  • CLN-978: A novel CD19xCD3 bispecific T cell engager being developed for systemic lupus erythematosus.
  • Zipalertinib: An EGFR inhibitor for non-small cell lung cancer, with promising efficacy and a manageable safety profile.

Financially, Cullinan is well-positioned, having announced a $280 million private placement to support ongoing research and development activities. This funding, combined with current assets, is expected to sustain the company's operations into 2028.

For more detailed insights and updates, visit Cullinan’s website or follow them on LinkedIn and Twitter.

Rhea-AI Summary

Cullinan Therapeutics has announced positive initial data from its Phase 2b REZILIENT1 study of zipalertinib for non-small cell lung cancer (NSCLC) with EGFR Exon 20 insertion mutations. The study involves patients who progressed after amivantamab treatment, showing a 39% objective response rate (ORR) and a 94% disease control rate (DCR). The data, cut off as of January 12, 2024, reflects findings in 31 patients with a median of three prior treatments. Zipalertinib had a manageable safety profile, with no grade 4 or 5 treatment-related adverse events. The company remains on track to complete enrollment by the end of 2024 and retains a 50/50 profit share in the U.S. through its partnership with Taiho. An investor event will be held on June 1, 2024, to discuss this and other data.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Cullinan Therapeutics, a biopharmaceutical company focused on developing targeted therapies, has announced that its CEO, Nadim Ahmed, and CMO, Jeffrey Jones, will participate in a fireside chat at the TD Cowen 5th Annual Oncology Innovation Summit.

The event, which will take place virtually on May 28 and 29, 2024, will feature their chat on May 29 at 11:30 am ET. A webcast of the event will be accessible on the company's investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.53%
Tags
conferences
-
Rhea-AI Summary

Cullinan Therapeutics announced preliminary data from its Phase 1 trial of CLN-619, an anti-MICA/B antibody, in combination with pembrolizumab, and updated monotherapy results. Among 22 patients treated with the combination, 3 showed partial responses, including in non-small cell lung cancer (NSCLC) and gastric cancer. Monotherapy results showed a 41.4% clinical benefit rate across various tumor types. CLN-619 was well tolerated, with most adverse events being mild. Cullinan is expanding the trial to include more NSCLC patients and has plans for further studies in multiple myeloma.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.53%
Tags
conferences
Rhea-AI Summary

Cullinan Therapeutics (Nasdaq: CGEM) reported its Q1 2024 financial results and provided corporate updates. Key highlights include a strong cash position with $434.8 million in cash and investments as of March 31, 2024, and an additional $280 million from an April private placement, extending its cash runway into 2028. The company appointed David Meek to its Board of Directors. Research and development (R&D) expenses decreased to $30.6 million, while general and administrative (G&A) expenses increased to $12.3 million for the quarter. Cullinan reported a net loss of $37.3 million for Q1 2024, down from $58.1 million in Q1 2023. Significant clinical developments include presenting data for CLN-619 at the ASCO 2024 Annual Meeting and focusing CLN-978 on autoimmune diseases, beginning with systemic lupus erythematosus (SLE). The company aims to complete enrollment for the Phase 2b REZILIENT1 study by year-end 2024 and has multiple data catalysts expected through early 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.89%
Tags
-
Rhea-AI Summary

Cullinan Therapeutics, Inc. (Nasdaq: CGEM) appoints Mary Kay Fenton as Chief Financial Officer, bringing three decades of experience in the biotechnology industry. Fenton will strengthen the company's financial and operational functions, aiming to accelerate growth and enhance shareholder value.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.19%
Tags
management
-
Rhea-AI Summary
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is set to present clinical data from its Phase 1 trial of CLN-619, a novel anti-MICA/B antibody, at the 2024 ASCO Annual Meeting. The data will include results from the dose escalation cohort of CLN-619 in combination with pembrolizumab and updated results from the monotherapy dose escalation cohort in patients with advanced solid tumors. CLN-619 targets stress-induced ligands to activate immune cells and shows potential for synergistic effects when combined with checkpoint inhibitors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.32%
Tags
conferences clinical trial
Rhea-AI Summary
Cullinan Therapeutics, formerly Cullinan Oncology, is strategically expanding into autoimmune diseases with a focus on systemic lupus erythematosus. The company's CLN-978 clinical development will target autoimmune diseases, showcasing promising results in B cell depletion and clinical activity. Cullinan Therapeutics will host a virtual investor event on April 16, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.65%
Tags
none
-
Rhea-AI Summary
Cullinan Therapeutics announces an oversubscribed $280 million private placement, extending cash runway into 2028. The financing includes new and existing leading life sciences institutional investors. Cullinan to host a virtual investor event on April 16 at 8:00 am ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.65%
Tags
none
-
Rhea-AI Summary
Cullinan Oncology, Inc. (Nasdaq: CGEM) reported strong financial results for Q4 and full year 2023. The company received FDA clearance for an IND to evaluate CLN-619 in multiple myeloma, with plans to present clinical data in Q2 2024. They are also exploring the development of CLN-978 for autoimmune disorders. Cash and investments stood at $468.3 million as of December 31, 2023, providing runway into the second half of 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
Rhea-AI Summary
Cullinan Oncology, Inc. (CGEM) to initiate Phase 1 study of CLN-619 for relapsed or refractory multiple myeloma, marking the first MICA/B antibody clinical study in hematologic malignancies. The FDA has cleared the Investigational New Drug (IND) application for CLN-619, a potential first-in-class humanized IgG1 monoclonal antibody. The company plans to start a Phase 1 trial to evaluate CLN-619 in patients with multiple myeloma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.22%
Tags

FAQ

What does Cullinan Therapeutics, Inc. specialize in?

Cullinan Therapeutics, Inc. specializes in developing innovative cancer and autoimmune therapies, utilizing a modality-agnostic approach to target key drivers of disease and harness the immune system.

What is CLN-617?

CLN-617 is a first-in-class cytokine therapy combining IL-2 and IL-12 for intratumoral injection, designed to activate a broad immune response against cancer cells.

What is the purpose of the recent $280 million private placement?

The $280 million private placement is intended to support Cullinan’s ongoing research and development activities, expand its clinical programs, and fund general corporate purposes and working capital.

What is Zipalertinib?

Zipalertinib is an orally available EGFR inhibitor designed to target exon 20 insertion mutations in non-small cell lung cancer, demonstrating promising efficacy and a manageable safety profile.

What are the latest developments regarding CLN-619?

CLN-619 is a monoclonal antibody targeting relapsed/refractory multiple myeloma, with Phase 1 trials indicating its potential to restore immune recognition and attack tumor cells.

What types of diseases does Cullinan Therapeutics' portfolio address?

Cullinan’s portfolio addresses both oncology and autoimmune diseases through a range of modalities designed to inhibit disease drivers or activate the immune system.

What is the strategic focus of Cullinan Therapeutics?

Cullinan focuses on creating transformative therapeutics by identifying unique targets and selecting optimal modalities, leveraging deep expertise in oncology, immunology, and translational medicine.

What is CLN-978 and its target indication?

CLN-978 is a novel CD19xCD3 bispecific T cell engager aimed at treating systemic lupus erythematosus and potentially other autoimmune diseases.

How does Cullinan Therapeutics ensure the development of promising assets?

Cullinan applies rigorous go/no-go criteria at each development stage to fast-track only the most promising molecules from candidate selection to clinical and commercial stages.

Where can I find more information about Cullinan Therapeutics?

More information about Cullinan Therapeutics can be found on their website at www.cullinantherapeutics.com and by following them on LinkedIn and Twitter.

Cullinan Oncology, Inc.

Nasdaq:CGEM

CGEM Rankings

CGEM Stock Data

1.34B
25.88M
6.4%
95.24%
3.33%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
CAMBRIDGE

About CGEM

cullinan oncology is focused on investing in and developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. sourced from the cullinan dry lab as well as external collaborators, cullinan’s assets are managed by a single, highly experienced team of oncology professionals and drug developers across a lean, capital efficient operating model.